

47. A method of claim 28 wherein the active enamel substance comprises amelogenins and has a molecular weight of about 60 kDa to about 120 kDa as determined by SDS Page electrophoresis.

48. A method for treating ectodermally derived benign, semi-malignant or malignant neoplasms, the method comprising administering topically to a mammal in need thereof a therapeutically effective amount of an active enamel substance.

49. A method of claim 48 wherein the ectodermally derived neoplasms are epithelially derived neoplasms.

50. A method of claim 48 or 49 wherein the active enamel substance comprises amelogenins and has a molecular weight of about 60 kDa to about 120 kDa as determined by SDS Page electrophoresis

51. A method of claim 48 wherein the ectodermally derived benign, semi-malignant or malignant neoplasms originate in a bodily tissue selected from the group consisting of glandular, bone, skin, ovarian and muscle tissue.

52. A method for treating conditions in a mammal characterized by the occurrence of ectodermally derived neoplastic cells, the method comprising administering topically to a mammal in need thereof a therapeutically effective amount of an active enamel substance.

53. A method of claim 52 wherein the active enamel substance comprises amelogenins and has a molecular weight of about 60 kDa to about 120 kDa as determined by SDS Page electrophoresis.

54. A method for treating ectodermally derived cancers and tumors, the method comprising administering topically to a mammal in need thereof a therapeutically effective amount of an active enamel substance.